(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Curcumin + doxorubicin)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Curcumin + doxorubicin) overview
Curcumin in combination with doxorubicin is under development for the treatment of chemo-resistant colon cancer, prostate cancer, esophageal cancer, nasopharyngeal cancer, soft tissue sarcoma, leiomyosarcoma, cholangiocarcinoma, carcinosarcoma, poorly differentiated sarcoma, triple negative breast cancer, ovarian, pancreatic cancers, malignant glioma, glioblastoma multiforme, multiple myeloma, colorectal cancer and solid tumor. It is a nanoparticle. Imx-110 is a first-in-class combination therapeutic candidate, that contains curcumin combined with a small amount of doxorubicin, encased in a nano-sized delivery system for optimal tumor penetration. Doxorubicin acts by targeting DNA and curcumin targets NF-kB/Stat3/pan-tyrosine kinase. The drug candidate is developed based on TME normalization technology.
Immix BioPharma overview
Immix BioPharma is a biopharmaceutical company focused on developing novel cancer therapies to combat resistant tumors. Its products portfolio includes Imx-109, a small-molecule agent used for the treatment of solid tumors; Imx-110, a nanoparticle delivery vehicle coloaded with small doses of cytotoxin and cytotoxic agents such as doxorubicin, paclitaxel, carboplatin, PD1 inhibitors, T Cell therapies for triple-negative breast cancer, ovarian cancer, colon cancer, and malignant glioma preclinical models. Immix BioPharma is developing therapy platform in the field of nanotechnology and drug delivery for the treatment of cancers. The company works in collaboration with other research institutes and universities for research and development of its cancer therapies. Immix BioPharma is headquartered in Los Angeles, California, the US.
For a complete picture of (Curcumin + doxorubicin)’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
